A real-world observational study of treatment patterns and outcomes for patients with neuromyelitis optica spectrum disorders (NMOSD) treated with inebilizumab (UPLIZNA) in EuropeFirst published 25/03/2024 Last updated 25/03/2024 EU PAS number: EUPAS1000000084StudyPlanned
Global Database Studies, IQVIACzechiaFinlandGermanySlovakiaSpain First published: 17/01/2011Last updated 31/07/2024 InstitutionOtherENCePP partner